Clinical experience with the combined use of lopinavir/ritonavir and rifampicin

Rafaëlla Fa L'homme; Hanneke M. J. Nijland; Luuk Gras; Rob E. Aarnoutse; Reinout van Crevel; Martin Boeree; Kees Brinkman; Jan M. Prins; Job R. Juttmann; David M. Burger

doi:https://doi.org/10.1097/QAD.0b013e328329148e

Clinical experience with the combined use of lopinavir/ritonavir and rifampicin

Rafaëlla Fa L'homme, Hanneke M. J. Nijland, Luuk Gras, Rob E. Aarnoutse, Reinout van Crevel, Martin Boeree, Kees Brinkman, Jan M. Prins, Job R. Juttmann, David M. Burger

Research output: Contribution to journal › Article › Academic › peer-review

41 Citations (Scopus)

Abstract

Thirty-four patients treated concomitantly with lopinavir/ritonavir and rifampicin were evaluated. Overall, only 15% used the recommended increased dose of lopinavir/ritonavir. Of patients on a nonadjusted dose of lopinavir/ritonavir, 67% had a subtherapeutic lopinavir plasma concentration and 38% had a detectable viral load. Forty percent of patients on an increased dose of lopinavir/ritonavir prematurely stopped the drug combination because of adverse events. Combined use of lopinavir/ritonavir and rifampicin is challenging as it implies balancing between suboptimal efficacy and toxicity

Original language	English
Pages (from-to)	863-865
Journal	AIDS (London, England)
Volume	23
Issue number	7
DOIs	https://doi.org/10.1097/QAD.0b013e328329148e
Publication status	Published - 2009

Access to Document

https://doi.org/10.1097/QAD.0b013e328329148e

Cite this

@article{4eaeb4785b6b495c9f8537242a1e20e7,

title = "Clinical experience with the combined use of lopinavir/ritonavir and rifampicin",

abstract = "Thirty-four patients treated concomitantly with lopinavir/ritonavir and rifampicin were evaluated. Overall, only 15% used the recommended increased dose of lopinavir/ritonavir. Of patients on a nonadjusted dose of lopinavir/ritonavir, 67% had a subtherapeutic lopinavir plasma concentration and 38% had a detectable viral load. Forty percent of patients on an increased dose of lopinavir/ritonavir prematurely stopped the drug combination because of adverse events. Combined use of lopinavir/ritonavir and rifampicin is challenging as it implies balancing between suboptimal efficacy and toxicity",

author = "L'homme, {Rafa{\"e}lla Fa} and Nijland, {Hanneke M. J.} and Luuk Gras and Aarnoutse, {Rob E.} and {van Crevel}, Reinout and Martin Boeree and Kees Brinkman and Prins, {Jan M.} and Juttmann, {Job R.} and Burger, {David M.}",

year = "2009",

doi = "https://doi.org/10.1097/QAD.0b013e328329148e",

language = "English",

volume = "23",

pages = "863--865",

journal = "AIDS (London, England)",

issn = "0269-9370",

publisher = "Lippincott Williams and Wilkins",

number = "7",

}

TY - JOUR

T1 - Clinical experience with the combined use of lopinavir/ritonavir and rifampicin

AU - L'homme, Rafaëlla Fa

AU - Nijland, Hanneke M. J.

AU - Gras, Luuk

AU - Aarnoutse, Rob E.

AU - van Crevel, Reinout

AU - Boeree, Martin

AU - Brinkman, Kees

AU - Prins, Jan M.

AU - Juttmann, Job R.

AU - Burger, David M.

PY - 2009

Y1 - 2009

N2 - Thirty-four patients treated concomitantly with lopinavir/ritonavir and rifampicin were evaluated. Overall, only 15% used the recommended increased dose of lopinavir/ritonavir. Of patients on a nonadjusted dose of lopinavir/ritonavir, 67% had a subtherapeutic lopinavir plasma concentration and 38% had a detectable viral load. Forty percent of patients on an increased dose of lopinavir/ritonavir prematurely stopped the drug combination because of adverse events. Combined use of lopinavir/ritonavir and rifampicin is challenging as it implies balancing between suboptimal efficacy and toxicity

AB - Thirty-four patients treated concomitantly with lopinavir/ritonavir and rifampicin were evaluated. Overall, only 15% used the recommended increased dose of lopinavir/ritonavir. Of patients on a nonadjusted dose of lopinavir/ritonavir, 67% had a subtherapeutic lopinavir plasma concentration and 38% had a detectable viral load. Forty percent of patients on an increased dose of lopinavir/ritonavir prematurely stopped the drug combination because of adverse events. Combined use of lopinavir/ritonavir and rifampicin is challenging as it implies balancing between suboptimal efficacy and toxicity

U2 - https://doi.org/10.1097/QAD.0b013e328329148e

DO - https://doi.org/10.1097/QAD.0b013e328329148e

M3 - Article

C2 - 19352137

SN - 0269-9370

VL - 23

SP - 863

EP - 865

JO - AIDS (London, England)

JF - AIDS (London, England)

IS - 7

ER -